Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

Next Previous
X
Search
Trial Profile

Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TPI 287 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cortice Bioscience; Cortice Biosciences

    • Most Recent Events

    • 21 Feb 2023 Planned End Date changed from 1 May 2023 to 1 May 2025.
    • 21 Feb 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2024.
    • 12 Nov 2020 Planned End Date changed from 1 Mar 2019 to 1 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top